Trump's key drug pricing advisor O'Brien makes HHS exit
Less than a year after being appointed senior advisor to the secretary for drug pricing reform — John O’Brien — is leaving the HHS, the agency disclosed on Monday.
O’Brien — who is a former PhRMA lobbyist and has previously worked with health insurer BlueCross BlueShield and the CMS — was considered one of the key architects of President Trump’s drug policy initiatives. He was promoted to his position in December 2018.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.